◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Ipca Laboratories Limited (IPCALAB) Revenue 2022–TTM

Name: Ipca Laboratories Limited (IPCALAB) revenue history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-03

Ipca Laboratories Limited annual revenue for fiscal TTM was ₹101.3 billion, an increase of 5.9% from ₹95.6 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

IPCALAB Annual Revenue

Revenue (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹101.3B	₹95.6B	₹88.5B	₹76.2B	₹62.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IPCALAB Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹27.9B	₹23.9B	₹23.9B	₹25.6B	₹23.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

GLENMARK Revenue — Glenmark Pharmaceuticals Limited
ALKEM Revenue — Alkem Laboratories Limited
ABBOTINDIA Revenue — Abbott India Limited
GLAND Revenue — Gland Pharma Limited
AJANTPHARM Revenue — Ajanta Pharma Limited
EMCURE Revenue — Emcure Pharmaceuticals Limited

More IPCALAB metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All IPCALAB financial statements → Interactive IPCALAB charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.